文献速递胸部肿瘤

TKI治疗EGFR罕见突变NSCLC术后复发患者的疗效

[Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

回顾性分析39例EGFR罕见突变NSCLC术后复发患者,TKI治疗组20例、非TKI组19例;TKI组复发后生存44个月优于非TKI组23个月(P=0.044),但两组术后总生存48 vs 43个月无显著差异(P=0.129)。结论建议此类患者术后复发采用TKI治疗。

要点

  • EGFR罕见突变中20号外显子发生率最高(20/39,51.3%)。
  • TKI组复发后生存44个月 vs 非TKI组23个月(P=0.044)。
  • 两组术后总生存48 vs 43个月,无显著差异(P=0.129)。

核心结论

  • EGFR罕见突变型NSCLC患者术后出现复发转移,建议采用TKI治疗。

研究设计与样本

  • 回顾性分析中国医学科学院肿瘤医院1999年1月至2013年12月术后复发且EGFR检测为罕见突变的NSCLC患者39例,TKI治疗组20例、非TKI治疗组19例。

主要发现

  • 39例中EGFR罕见突变以点突变和插入突变为主,20号外显子发生率最高(20/39,51.3%)。
  • 罕见点突变共13种,位于18、20和21号外显子,21号外显子点突变7种。
  • 18号外显子G719S/C/A是最常见点突变类型(14/25,56.0%)。
  • TKI组术后复发后生存44个月 vs 非TKI组23个月(P=0.044)。
  • 两组术后总生存48 vs 43个月,无显著差异(P=0.129)。

临床怎么用

  • EGFR罕见突变NSCLC患者术后出现复发转移时,可采用TKI治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the efficacy of tyrosine kinase inhibitor (TKI) treatment on non-small cell lung cancer (NSCLC) patients with postoperative recurrence who harbored uncommon EGFR mutations, and discuss the relationship between TKI treatment and prognosis. Methods: A total of 39 relapsed NSCLC patients after surgery with EGFR uncommon mutations who were detected at Cancer Hospital, Chinese Academy of Medical Sciences between January 1999 and December 2013 were retrospectively analyzed in this study. Twenty patients were treated with EGFR-TKI after recurrence and 19 cases were not. The clinical characteristics of patients with EGFR uncommon mutations were evaluated, and the prognosis of TKI-treatment group and non-TKI treatment group was compared. Results: In 39 relapsed NSCLC patients with EGFR uncommon mutations, insertion mutations and point mutations were included. The highest frequency of EGFR uncommon mutation happened in exon 20 (20/39, 51.3%). A total of 13 uncommon point mutations were detected in exon 18, 20 and 21. The most frequent rare point mutations located in exon 21, and there were 7 different point mutation sites in exon 21. G719S/C/A mutation in exon 18 was the most common type of point mutation (14/25, 56.0%). Survival after postoperative recurrence in TKI treatment group was obviously better than that in non-TKI treatment group, the median time after recurrence were 44 months and 23 months, respectively (P=0.044). However, the postoperative overall survival showed no differences between two groups (48 months vs 43 months, P=0.129). Conclusion: NSCLC patients with postoperative recurrence who harbored rare EGFR mutations should be treated with TKI agent. 目的: 分析表皮生长因子受体(EGFR)罕见突变非小细胞肺癌术后复发患者的临床病理特征,探讨其与酪氨酸激酶抑制剂(TKI)治疗的关系。 方法: 收集中国医学科学院肿瘤医院1999年1月至2013年12月,术后复发且经EGFR基因检测证实为EGFR罕见突变的非小细胞肺癌患者39例,分为TKI治疗组(20例)和非TKI治疗组(19例),分析EGFR罕见突变类型患者的临床病理特征,比较TKI治疗组和非TKI治疗组术后复发患者的预后。 结果: 39例术后复发的非小细胞肺癌患者中,EGFR基因罕见突变类型主要为点突变和嵌入突变,20号外显子EGFR罕见突变的发生率最高(20/39,51.3%);罕见点突变共发现13种,分别位于18、20和21号外显子,其中21号外显子的点突变发生率最高(7种);18号外显子的G719S/C/A突变是最常见的点突变类型(14/25,56.0%)。TKI治疗组患者术后复发的生存时间(44个月)长于非TKI治疗组(23个月),差异有统计学意义(P=0.044);但两组患者的术后总生存时间分别为48和43个月,差异无统计学意义(P=0.129)。 结论: EGFR罕见突变型非小细胞肺癌患者术后出现复发转移,建议采用TKI治疗。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang WJ, Gao YB, Qiu T, et al. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 29061015. doi:10.3760/cma.j.issn.0253-3766.2017.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。